Drug Profile
Erythropoietin biosimilar - Pooyesh Darou
Latest Information Update: 13 Jul 2022
Price :
$50
*
At a glance
- Originator Pooyesh Darou
- Class Antianaemics; Erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 18 Feb 2022 No development reported - Phase-I/II for Solid tumours in Iran (SC)
- 16 Oct 2017 Iran University of Medical Sciences, Mashhad University of Medical Sciences, Shiraz University of Medical Sciences, Tabriz University of Medical Sciences and Tehran University of Medical Sciences plan the phase III TONTT-2 trial for traumatic optic neuropathy (In children, In adolescents, In adults) in Iran (IV) (NCT03308448)
- 23 Jul 2015 Pooyesh Darou completes enrolment in its phase I/II trial for Solid tumours in Iran (IRCT2015061822805N1)